On the basis of an empty – and therefore non-infectious – shell of a phage virus, researchers from Berlin have developed a chemically modified phage capsid that “stifles” influenza viruses. Perfectly fitting binding sites cause influenza viruses to be enveloped by the phage capsids in such a way that it is practically impossible for them to infect lung cells any longer.
This phenomenon has been proven in pre-clinical trials, also involving human lung tissue. Researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Freie Universität Berlin, Technische Universität Berlin (TU), Humboldt-Universität (HU), the Robert Koch Institute (RKI) and Charité-Universitätsmedizin Berlin were involved in this groundbreaking work. The results are also being used for the immediate investigation of the coronavirus. The findings have now been published in Nature Nanotechnology.
Influenza viruses are still highly dangerous: The World Health Organization (WHO) estimates that flu is responsible for up to 650,000 deaths per year worldwide. Current antiviral drugs are only partially effective because they attack the influenza virus after lung cells have been infected. It would be desirable – and much more effective – to prevent infection in the first place.
This is exactly what the new approach from Berlin promises. The phage capsid, developed by a multidisciplinary team of researchers, envelops flu viruses so perfectly that they can no longer infect cells. “Pre-clinical trials show that we are able to render harmless both seasonal influenza viruses and avian flu viruses with our chemically modified phage shell,” explained Professor Dr. Christian Hackenberger, Head of the Department Chemical Biology at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and Leibniz Humboldt Professor for Chemical Biology at HU Berlin. “It is a major success that offers entirely new perspectives for the development of innovative antiviral drugs.”
Multiple bonds fit like hook-and-loop tape
The new inhibitor makes use of a feature that all influenza viruses have: There are trivalent receptors on the surface of the virus, referred to as hemagglutinin protein, that attach to sugar molecules (sialic acids) on the cell surface of lung tissue. In the case of infection, viruses hook into their victim – in this case, lung cells – like a hook-and-loop fastener. The core principle is that these interactions occur due to multiple bonds, rather than single bonds.
It was the surface structure of flu viruses that inspired the researchers to ask the following initial question more than six years ago: Would it not be possible to develop an inhibitor that binds to trivalent receptors with a perfect fit, simulating the surface of lung tissue cells?
We now know that this is indeed possible – with the help of a harmless intestinal inhabitant: The Q-beta phage has the ideal surface properties and is excellently suited to equip it with ligands – in this case sugar molecules – as “bait”. An empty phage shell does the job perfectly. “Our multivalent scaffold molecule is not infectious, and comprises 180 identical proteins that are spaced out exactly as the trivalent receptors of the hemagglutinin on the surface of the virus,” explained Dr. Daniel Lauster, a former PhD student in the Group of Molecular Biophysics (HU) and now a postdoc at Freie Universität Berlin. “It therefore has the ideal starting conditions to deceive the influenza virus – or, to be more precise, to attach to it with a perfect spatial fit. In other words, we use a phage virus to disable the influenza virus!”
To enable the Q-beta scaffold to fulfill the desired function, it must first be chemically modified. Produced from E. coli bacteria at TU Berlin, Professor Hackenberger’s research group at FMP and HU Berlin use synthetic chemistry to attach sugar molecules to the defined positions of the virus shell.
Virus is deceived and enveloped
Several studies using animal models and cell cultures have proven that the suitably modified spherical structure possesses considerable bond strength and inhibiting potential. The study also enabled the Robert Koch Institute to examine the antiviral potential of phage capsids against many current influenza virus strains, and even against avian flu viruses. Its therapeutic potential has even been proven on human lung tissue, as fellow researchers from the Medical Department, Division of Infectiology and Pneumology, of Charité were able to show: When tissue infected with flu viruses was treated with the phage capsid, the influenza viruses were practically no longer able to reproduce.
The results are supported by structural proof furnished by FU scientists from the Research Center of Electron Microscopy (FZEM): High-resolution cryo-electron microscopy and cryo-electron microscopy show directly and, above all, spatially, that the inhibitor completely encapsulates the virus. In addition, mathematical-physical models were used to simulate the interaction between influenza viruses and the phage capsid on the computer. “Our computer-assisted calculations show that the rationally designed inhibitor does indeed attach to the hemagglutinin, and completely envelops the influenza virus,” confirmed Dr. Susanne Liese from the AG Netz of Freie Universität Berlin. “It was therefore also possible to describe and explain the high bond strength mathematically.”
Therapeutic potential requires further research
These findings must now be followed up by more preclinical studies. It is not yet known, for example, whether the phage capsid provokes an immune response in mammals. Ideally, this response could even enhance the effect of the inhibitor. However, it could also be the case that an immune response reduces the efficacy of phage capsids in the case of repeated-dose exposure, or that flu viruses develop resistances. And, of course, it has yet to be proven that the inhibitor is also effective in humans.
Nonetheless, the alliance of Berlin researchers is certain that the approach has great potential. “Our rationally developed, three-dimensional, multivalent inhibitor points to a new direction in the development of structurally adaptable influenza virus binders. This is the first achievement of its kind in multivalency research,” emphasized Professor Hackenberger. The chemist believes that this approach, which is biodegradable, non-toxic and non-immunogenic in cell culture studies, can in principle also be applied to other viruses, and possibly also to bacteria. It is evident that the authors regard the application of their approach to the current coronavirus as one of their new challenges. The idea is to develop a drug that prevents coronaviruses from binding to host cells located in the throat and subsequent airways, thus preventing infection.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Suppressing seasonal influenza
- Oxford COVID vaccine on track for OCTOBER release ahead of flu season 'Very good results'on June 22, 2020 at 3:00 pm
A CORONAVIRUS vaccine being developed by scientists at the University of Oxford is expected to be ready in time for the winter flu season - amid fears of a possible second wave of COVID-19.
- How likely are kids to get Covid-19? Scientists see a ‘huge puzzle’ without easy answerson June 19, 2020 at 5:13 pm
Much of the evidence has been conflicting, but scientists remain hopeful children are less likely to catch the virus and less likely to spread it.
- As coronavirus cases rise in Victoria, how do we know when a second wave is starting?on June 19, 2020 at 12:00 pm
"For the Spanish flu, what you saw was the seasonal effect of the virus actually disappearing ... "We're hoping not to have a second wave, we're hoping to be able to continue with our suppression ...
- WHO urges nations to prepare for Influenza amidst coronavirus pandemicon June 17, 2020 at 9:23 am
Click to read all about coronavirus → The World Health Organisation (WHO) says the world must not lose sight of significant public health issues like influenza which affects eve ...
- Health and Hospitals preps for fall resurgence of Covid-19on June 15, 2020 at 8:59 am
As Covid-19 cases, hospitalizations and deaths trend down in New York City, the leadership team at Health and Hospitals is focused on autumn and the possibility that a Covid-19 resurgence could ...
Go deeper with Google Headlines on:
Suppressing seasonal influenza
Go deeper with Bing News on:
Suppressing avian flu
- A New Look at Old Pandemicson June 18, 2020 at 10:31 am
Mike Davis's 2005 study of the risks of an avian flu pandemic has come back with a vengeance in the time of COVID-19.
- How a pandemic thriller went from desk drawer to bestseller in a monthon June 18, 2020 at 8:02 am
Returning to the concept in 2005, he used the avian flu, which some scientists predicted would be the next pandemic (and which is far more lethal than SARS or COVID-19). But instead of Beijing ...
- Study shows 1 in 15 parents is hesitant about routine childhood vaccineson June 15, 2020 at 12:44 am
As of 2018-2019, just 57.9% of American children were vaccinated against influenza. "That means in any given year more than 40% of children are not vaccinated against influenza," Kempe said. "We ...
- No hard scientific evidence showing there are less virulent strains, says virologist Malik Peirison June 13, 2020 at 5:02 am
In the case of COVID-19, patients are transmitting immediately from the time they develop symptoms and even before.
- From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruseson June 11, 2020 at 4:25 am
Influenza A virus causes a highly immunogenic acute infection but never leads to a chronic disease. While oncolytic influenza A viruses are in preclinical development, they have not made the ...